Novel Therapeutic Targets in Melanoma.


Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
25 Jan 2023
Historique:
received: 23 12 2022
accepted: 17 01 2023
entrez: 11 2 2023
pubmed: 12 2 2023
medline: 12 2 2023
Statut: epublish

Résumé

Melanoma is the most aggressive skin cancer type and ranks amongst the deadliest cancers due to its ability to develop resistance to current therapies [...].

Identifiants

pubmed: 36765705
pii: cancers15030747
doi: 10.3390/cancers15030747
pmc: PMC9913784
pii:
doi:

Types de publication

Editorial

Langues

eng

Références

Cancers (Basel). 2022 Jul 11;14(14):
pubmed: 35884430
Cancers (Basel). 2022 Jan 06;14(2):
pubmed: 35053435
Cancers (Basel). 2021 Nov 03;13(21):
pubmed: 34771678
Cancers (Basel). 2021 Nov 27;13(23):
pubmed: 34885078
Cancers (Basel). 2022 Jan 29;14(3):
pubmed: 35158973
Cancers (Basel). 2022 Apr 23;14(9):
pubmed: 35565234
Cancers (Basel). 2021 Dec 08;13(24):
pubmed: 34944799
Cancers (Basel). 2021 Jul 15;13(14):
pubmed: 34298765
Cancers (Basel). 2021 Dec 07;13(24):
pubmed: 34944771
Cancers (Basel). 2022 May 16;14(10):
pubmed: 35626062

Auteurs

Michaël Cerezo (M)

INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Equipe 12, Bâtiment ARCHIMED, 151 Route de St Antoine de Ginestière, BP2 3194, CEDEX 3, 06204 Nice, France.

Stéphane Rocchi (S)

INSERM, U1065, Centre Méditerranéen de Médecine Moléculaire (C3M), Université Côte d'Azur, Equipe 12, Bâtiment ARCHIMED, 151 Route de St Antoine de Ginestière, BP2 3194, CEDEX 3, 06204 Nice, France.

Classifications MeSH